D. Boral Capital Reiterates Buy Rating on ImmunityBio

Summary

D. Boral Capital reiterated its ‘buy’ rating for ImmunityBio (NASDAQ: IBRX) with a target price of $30.00. Other analysts, including Piper Sandler and HC Wainwright, also have positive ratings for the stock with target prices of $5.00 and $8.00, respectively. ImmunityBio opened at $2.67, with a 52-week range of $1.83 to $7.63. The company reported a quarterly loss of $0.15 per share, missing expectations, and forecasts a full-year loss of -$0.92 per share. Institutional investors hold 8.58% of the company’s shares.Market Beat

Impact Analysis

The event is at the company level, focusing on ImmunityBio’s stock ratings and target prices. D. Boral Capital’s high target price of $30.00 significantly exceeds those of Piper Sandler and HC Wainwright, indicating a strong bullish stance. This discrepancy may cause mixed perceptions among investors. ImmunityBio’s recent earnings miss and projected annual loss may temper investor enthusiasm despite positive analyst ratings. The reaffirmation and updates of ratings by multiple analysts could lead to increased trading volumes and potential short-term stock price movements as investors react to these opinions. Institutional investors’ 8.58% stake suggests a moderate level of confidence in the company’s prospects, but the market may wait for further operational updates or product pipeline developments to align with higher price targets.Market Beat+ 2